price close busi april
leader comprehens liquid
biopsi profil cancer patient offer suit
test includ flagship test across
area like therapi select advanc initi
recurr monitor later earli detect
cancer lunar program guardant
estim us billion
diagnost tool
initi coverag
acceler mission
conquer cancer global initi buy pt
hope initi coverag gh sooner find
situat investor ask move sinc oct ipo justifi
stock go higher say ye view
leader liquid biopsi cancer test laser focus build mass data
prove clinic econom util test help cancer patient live longer
right target therapi therapi select perform recurr monitor
american cancer survivor today later screen higher-risk
american cancer simpl blood test across rang cancer combin
us-alon meanwhil gh look replic work ou initi japan
initi buy rate pt use multipl revenue
estim discount back year
leader liquid biopsi cancer test estim gh penetr us
liquid biopsi therapi select flagship blood test
order oncologist oncologist sinc launch
nile studi shift tumor test liquid biopsi read last month
nile trial identifi guideline-recommend biomark liquid
biopsi test standard-of-car ffpe tissu test data think may turn soc
upsid shift blood first paradigm rather tissue-first soc
fda approv pan-canc label guardant expect submit
fda break-through devic approv expect fda approv
end think reduc pushback remain
us-bas oncologist yet order believ pan-canc label
meaning expand opportun greater util across solid tumor cancer
patient commonli order non-smal cell lung cancer patient
pan-canc medicar coverag big deal help landmark
march decis gh expect coverag solid tumor cancer
limit nsclc huge opportun expect commerci payor follow
across cancer state gh live includ medicar nsclc alon
launch dec research use gh launch promis
test us-bas cancer survivor recurr monitor residu
diseas detect gh size us clinic launch date clear
gh rapidli advanc data develop blood-bas test
screen earli detect asymptomat high-risk american
solid tumor cancer lung colon breast ovarian other holi grail precis
medicin gh size us think could launch ahead grail
ideal companion diagnost partner ask astrazeneca gh ink two
companion diagnost deal astrazeneca one intend identifi addit
patient elig treat osimertinib tagrisso drug nsclc today
could potenti reach peak sale durvalumab imfinzi
gh test use lead biopharma compani
us japan ou huge estim guardant global
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
initi coverag
advanc mission
conquer cancer global initi buy pt
hope initi coverag guardant month sooner instead
similar situat investor ask move sinc oct
ipo justifi stock go higher
say ye question see upsid ahead sever near-term catalyst
see figur catalyst tabl background massiv opportun
guardant transit late-stag liquid biopsi test early-stag liquid biopsi
screen view leader liquid biopsi oncolog test
laser focus build mass data prove clinic econom util
test help cancer patient live longer right therapi target
therapi select perform recurr monitor american cancer
survivor today later screen higher-risk american cancer
simpl blood test across rang cancer combin us-alon gh peg
meanwhil gh advanc work ou initi japan strong jv
partner softbank initi coverag buy rate
pt use multipl revenue estim discount back
year discount rate dilut share outstand
guardant clear leader liquid biopsi test cancer liquid biopsi
test get start estim penetr
annual total metastat cancer patient us
guardant size us therapi select consist estim
clinic opportun assum patient test
cours diseas guardant see anoth annual therapi select
opportun pharma test alreadi order
oncologist us-bas oncologist sinc launch
model assum guardant add roughli point market share penetr
therapi select market year go forward
think could conserv guardant obtain fda approv obtain pan-
cancer medicar approv doubl sale forc rep later
estim guardant liquid biopsi market share liquid
fda approv pan-canc label guardant expect submit
flagship test fda break-through devic approv
anticip fda approv end think reduc
pushback remain us-bas doc yet order
believ pan-canc label meaning expand gh
opportun far greater util across solid tumor cancer patient
commonli order non-smal cell lung cancer
pan-canc medicar coverag help landmark march
decis guardant expect reimburs medicar solid tumor cancer
state today limit non-smal cell lung cancer nsclc like
see larg increment opportun expect commerci payor follow
across cancer state total live includ medicar
present limit nsclc alon
nile studi shift tumor test liquid biopsi acceler growth rate
clinic volum last month guardant read data
import nile trial went head-to-head liquid vs tissu demonstr
guardant panel identifi guideline-recommend biomark
liquid biopsi test standard-of-car ffpe tissu test data
think may turn ffpe tissu test standard-of-car upside-down shift
diagnost tool
initi coverag
blood first paradigm rather tissue-first standard-of-car highlight specif
studi later initi report
decemb guardant launch cancer recurr
monitor assay research use pharma test aim
monitor us-bas cancer survivor cancer recurr residu
diseas detect gh size us asp
us-bas cancer survivor launch today research-us
guardant plan launch clia version investig use
prospect studi guardant yet commun time full blown
commerci launch cancer patient suspect sometim
see potenti strong futur uptak minim
residu diseas recurr detect cancer survivor cancer
lung colon breast ovarian cancer among mani cancer state
gh rapidli advanc data develop blood-bas test
intend screen earli detect million asymptomat high-
risk american wide rang solid tumor cancer lung colon breast ovarian
cancer other -- perhap holi grail precis medicin guardant size
unit state alon assum million american
test price guardant also hope launch outsid
unit state like initi japan larg market high incid cancer
american associ cancer research confer featur nile studi
data addit early-stag colon detect data guardant recent
present abstract month expand upon earli data
publish nile studi therapi select advanc nsclc blood vs tissu
program earli detect colon cancer cancer
highlight data later report
guardant ideal companion diagnost partner ask astrazeneca guardant
ink two import companion diagnost cdx deal astrazeneca
one identifi addit patient elig treat osimertinib tagrisso
gh believ may reach peak sale anoth azn immuno-
oncolog drug durvalumab imfinzi gh test use lead
biopharma compani believ guardant ideal companion diagnost
partner well posit pursu addit cdx deal lead pharma
compani come year guardant close work pharma never
afterthought core part strategi begin note
astrazeneca one sever pharma compani help develop
guardantomni other includ merck bm guardant sign non-
exclus deal astrazeneca thu think like time guardant
look work number lead pharma compani close
guardant ramp invest ou size global tam talk
plan advanc may privat compani
radar screen mani investor commun announc
format joint ventur softbank part privat round financ
net guardant million one round financ softbank row price
temasek exist investor sequoia capit khosla ventur lightspe
ventur partner orbim strong syndic addit lead
round fund softbank form joint ventur guardant expand
commerci guardant liquid biopsi technolog asia middl east
africa time announc guardant estim nearli million new
cancer diagnos year asia middl east africa
diagnost tool
initi coverag
masayoshi chairman softbank group time indic
appli breakthrough technolog machin learn
genom cancer one world biggest challeng guardant approach
built smart scienc smart busi model capabl grow
time doctor use servic invest enabl guardant alreadi
clear leader excit field becom cancer across
figur despit catalyst-rich alreadi see mani catalyst ahead beyond
diagnost tool
initi coverag
guardant target huge unit state around billion
estim market opportun current commerci pipelin product
 alon consist applic clinician biopharma
custom address earli late-stag diseas
figur guardant size total address market opportun us alon approxim billion
market us therapi select late stage cancer patient billion
offer flagship market-lead liquid biopsi
test therapi select market sinc gh peg market us
assum clinic opportun patient test
cours diseas anoth annual therapi select
opportun pharma guardant peg biopharma opportun
assum tests/year price pharma note price
pharma medicar clinic reimburs gh point
pharma industri clinic pipelin immuno-oncolog program
target therapi program trial involv patient gh seek
add valu stage pharma drug develop includ prospect
diagnost tool
figur guardant drive meaning sale pharma partner part due higher versu clinic custom
initi coverag
market us recurr detect cancer survivor billion
american cancer societi estim million solid
tumor cancer survivor guardant assay seek improv survivorship
cure patient outcom screen cancer survivor cancer recurr
residu diseas believ billion market opportun
assay refin base biolog insight patient test
test report genom alter allel frequenc
filter disrupt biolog nois incorpor epigenom signatur
gh believ differenti test compani like ntra-
 buy roch foundat medicin
market us earli detect cancer higher-risk peopl billion
base inform center diseas control prevent censu
data publish medic literatur guardant estim
approxim million individu unit state meet criteria
higher risk cancer
million individu moder high famili risk develop cancer
sourc genet medicin
million smoker age sourc cdc
individu us high risk develop liver cancer due hepat
infect sourc hepatolog given significantli larger potenti patient
popul gh assum averag sell price
test therapi select medicar rate guardantomni
estim sold pharma compani
diagnost tool
huge tam estim
global total address market
figur believ gh penetr estim global tam approxim gh estim us alon
initi coverag
regard guardant larg make follow observ
guardant estim billion us market alon howev
guardant made invest outsid unit state notabl japan
jv softbank guardant clinic trial japan larg
affluent single-payor health system guardant estim
billion also expect gh advanc commerci footprint across europ
part asia australia countri start point time
cost sequenc declin think guardant could expand product
world
last year lot investor focu came grail form
ilmn-nasdaq buy grail may come market
theyv slow gate higher visibl guardant
commerci path market earli screen ahead grail use blood
test thu could first big mover holi grail
earli stage suit highli accur blood-bas screen test earli
detect cancer expect guardant acceler invest hope
compet exas-nasdaq buy colorect
cancer screen note gh go higher-risk american
alreadi fda-clear guidelin average-risk american thu two
approach entir apples-to-appl
guardant initi pursu earli detect cancer higher-risk
individu think gh may end guardant continu seek
optim sensit specif thu compani continu leverag
machin learn advanc platform believ could someday
meaning expand includ earli detect cancer low-
average-risk asymptomat patient market grail
intend pursu begin investor present
parent compani indic grail target base case
billion high-risk individu test everi year
diagnost tool
initi coverag
bull case billion million all-risk
patient test everi year
relat guardant recurr monitor us
compani estim one test/patient/year think unreason
think recurr monitor guardant may pathway two
tests/person/year impli us recurr monitor billion
us year
peg market opportun current commerci pipelin
product alon includ
opportun advanced-stag cancer therapi select
assum clinic opportun patient test
cours diseas anoth annual therapi select opportun
pharma tests/year price pharma note
price pharma medicar clinic reimburs
opportun recurr monitor cancer survivor patient
opportun screen earli detect asymptomat high-risk
individu patient
accord model gh penetr base expect
gh rev rel global enterpris valu global
key comp estim fmi acquir
roch total consider billion
nation institut estim year new
case cancer diagnos individu die
diseas estim cancer survivor unit
state number nih expect rise
understand cultur environment genet factor lead
vari cancer incid rate differ countries/region weve attempt
understand guardant develop global market opportun expect publish
in-depth analysi futur purpos initi
estim gh ou market opportun rough analysi compar
number new cancer diagnos certain region estim new
diagnos year accord epidemiolog sourc consist
guardant commentari cancer diagnos japan year
would size market follow
methodolog key eu countri germani uk franc itali spain would
compris market assum estim new cancer diagnos
year china estim new cancer diagnos year
accord ac appli major asp haircut given structur differ
china healthcar system arriv conserv market opportun
ad project nordic countri opportun brazil
opportun canada opportun australia opportun arriv
estim market opportun across therapi select recurr
monitor earli screen exclud central south american
countri outsid brazil africa unment asian countri unment
european countri middl eastern countri next year expect
guardant meaning increas global market penetr today
driven steadi stream clinic evid data
global tam estim shown figur comp group base compani
present addit canaccord genuiti estim comp group assum
diagnost tool
launch cologuard ou fmi grow
revenu guid provid prior
compani acquisit roch intern cancer rate estim base
world cancer research fund age-standard cancer rate countri
figur guardant present offer develop wide array test clinic pharma/research use across applic
initi coverag
time fall decemb order time oncologist biopharma compani
diagnost tool
figur divers guardant offer address unmet need larg market span billion us alon
initi coverag
reason buy guardant health
get start larg global market peg
guardant share comprehens genom profil cgp market
think meaning room grow build cgp market
us global visibl potenti multipl year
double-digit growth cgp becom readili avail cancer patient
improv reimburs public also estim
penetr term revenu dollar global
estim billion
rel new simpl altern invas tissu biopsi
guardant use late stage cancer patient ensur treat
correct drug save money avoid incorrect treatment simpl blood test
less invas expens tissu biopsi cost per
biopsi accompani complic rate time accord
publish studi journal oncolog practice/clin lung cancer lung biopsi
complic includ hemorrhag respiratori failur
plan submiss fda mid-year may set guardant
fda-clear test late earli guardant plan submit flagship
test fda mid-year fda approv guardant obtain
breakthrough devic design fda facilit acceler
review process guardant estim review time month test
strong success alreadi lab-develop test ldt believ fda
approv acceler growth help drive addit commerci
payor win well uptick order clinician may prefer order
fda-clear test recogn fda-approv stamp approv
diagnost tool
initi coverag
importantli fda approv also enabl guardant qualifi pan-canc medicar
fda-clear enabl guardant qualifi pan-canc medicar
nation coverag determin ncd help landmark next-
gener sequenc coverag decis march gh expect coverag
solid tumor cancer limit nsclc big opportun
expect commerci payor follow across cancer state gh live
nsclc alon includ medicar approxim test order
today lung cancer addit cancer commonli
compris colon breast prostat ovarian cancer
signific strateg partnership guardant pharma partner
leverag network includ partnership astrazeneca develop
guardant project design help clinician screen
detect cancer recurr earli stage increas success rate intervent
test initi focu lung colorect breast ovarian cancer
early/preliminari data small project earli stage
develop said success could provid signific upsid
compani year
earli data guardant abstract shown preliminari data
promis notabl guardant demonstr sensit
specif earli stage colorect cancer detect howev note
compani sampl size small much larger studi would need conduct
keep accuraci similar better percentag estim bogey
fda-clear early-stag cancer test better sensit
better specif point cologuard test sensit
specif obtain fda approv medicar coverag sinc
ad number guidelin includ uspstf nccn
price increas guardant negoti directli commerci health
plan coverag determin addit contract certain rate
manag indic commerci payor rate well
medicar rate pama guardant medicar rate deriv
weight averag median commerci payor given dynam
understand guardant like see increas medicar rate
begin believ addit revenu
compani overview histori
found helmi eltoukhi phd amirali talasaz
phd serv guardant ceo chairman/president/coo respect
guardant develop commerci non-invasive blood-bas cancer
diagnost test base proprietari technolog includ differenti
chemistri approach broad data set advanc analyt guardant launch
flagship test gh becam public compani octob
rais wide oversubscrib ipo gh headquart redwood
decemb guardant full-tim employe
technolog bd lab commerci oper function
time estim gh full-tim territori sale rep compani
look expand end year sooner guardant leas space
headquart redwood citi sinc may includ squar
diagnost tool
initi coverag
feet space gh clia-certifi laboratori guardant outlin plan
futur capac expans
septemb guardant enter suppli agreement
suppli sequenc reagent consum use gh lab agreement
extend decemb automat renew addit one-year term
guardant core strength competit advantag includ
biochemistri next-gen sequenc signal process bioinformat machin
learn process engin high perform clinic comprehens liquid
biopsi result time day
clinic util guardant look build credibl clinic research
strateg relationship lead biopharmaceut compani gh invest
heavili clinic studi includ clinic outcom studi largest-ev
liquid-to-tissu concord studi prospect intervent clinic util
studi demonstr clinic overal respons rate line tissu biopsi
approach guardant clinic research collabor result
peer-review public relationship biopharmaceut
regulatori approv guardant look drive adopt improv reimburs
test secur regulatori approv liquid biopsi offer guardant
plan submit fda expect fda approv late
follow fda approv guardant look secur pan-
cancer medicar coverag guardant also expect take guardantomni
gene panel design pharma fda pma process
one first comprehens liquid biopsi test approv
new york state depart nysdoh compani facil
first comprehens liquid biopsi laboratori clia-certifi cap-accredit
payer coverag reimburs current cover
live unit state includ coverag sever cross
shield plan hcsc medicar adopt reimburs polici
cover non-smal cell lung cancer nsclc believ fda
approv pan-canc medicar coverag like help increas coverag
reimburs
commerci adopt guardant clinic data relationship key
stakehold oncolog commun help facilit adopt
oncologist collect order test
diagnost tool
figur guardant make strong stride advanc clinic adopt pharma use evid reimburs regulatori pursuit
initi coverag
time fall
bolt-on acquisit march guardant enter definit agreement
acquir bellweth privat held compani spun univers
washington bellweth diagnost applic involv detect epigenet
signal circul cell free dna guardant believ improv clinic
perform blood test earli stage cancer detect incorpor
geneticist train georg church head univers washington
shendur lab act scientif advisor transact
expect close april term deal disclos
recent result gh drove revenue growth
oper result guid gh report revenu million
y/i beat consensu gh report test clinic
custom y/i test biopharmaceut custom y/i
precis oncolog revenu y/i nearli doubl due increas order
clinician pharma partner higher revenu
per test follow launch higher-pr guardantomni full-year
guardant gener revenu y/i gross margin
came y/i driven extra payment medicar higher
blend cogs/test improv oper expens
y/i oper expens full year
y/i note rare compani stage demonstr materi
faster revenu growth growth oper expens suggest
believ strong uptak clinic pharmaceut offer gross margin
net loss came
per share full year gh record net loss
contempl quarter limit share outstand pre-ipo guardant
complet ipo octob rais net proce guardant
exit healthi cash balanc sheet level believ
unusu high compani stage pre-ipo guardant receiv signific
capit infus softbank jv partner japan
diagnost tool
initi coverag
revenue guid growth look beatabl
compani call march guardant initi revenu guidanc
rang y/i indic expect revenu
heavili weight expect larger payment astrazeneca
companion diagnost agreement earlier year guardant guid clinic
sampl volum rang test y/i given strong
momentum across compani busi guardantomni
revenu come research pharmaceut sourc follow strong
data nile studi believ room upsid rel
guardant guid net loss increas invest
direct sale forc believ roughli doubl direct sale rep lunar
program ou growth includ japan
guardant expect clinic pharma revenu similar size
higher omni off-set smaller number sampl pharma
model near term assumpt thought model
revenu y/i consensu
compani guidanc model clinic test volum
y/i vs gh guid pharma test volum y/i
model revenu growth
respect street estim vari
consensu call revenu growth
model clinic revenu growth pharma revenu growth
driven strong volum gain rise particularli pharma driven
launch higher-pr guardantomni estim asp
 assum gross margin expans result
gm driven price benefit higher price omni test
improv reimburs volum growth model opex
y/i driven rise cost continu
invest commerci team look scale rep last
year carri forward assumpt modest y/i gm expans may
prove conserv continu outsiz invest growth model
profit gm assum continu pace outsiz
invest opex year gh invest heavili volum growth
model estim revenu y/i ep
gross margin oper margin
diagnost tool
initi coverag
 technolog product
dna sequenc process determin nucleic acid sequenc dna
guardant use state-of-the-art technolog guardant digit sequenc
technolog leverag high-effici biochemistri machin learn
augment bioinformat pipelin next-gener sequenc guardant
machin learn capabl help differenti sequenc approach
contribut perform assay sampl volum grown goal
guardant digit sequenc technolog use advanc molecular biolog novel
chemistri bioinformat maxim nucleic acid yield minim error
relat sequenc
compani flagship blood test therapi select
assay compani flagship test launch
wide use comprehens liquid biopsi test gene
test support treatment select advanc stage cancer patient solid
tumor test process requir two millilit blood sampl sent
gh lab redwood citi ca end
order time us-bas oncologist look genom
alter tumor dna patient advanc cancer support
peer-review journal public scientif abstract clinic
studi address analyt valid clinic valid clinic util
order first-lin test determin therapi may
effect advanc stage cancer patient advanc solid tumor
molecular test incomplet unobtain limit patient egfr
neg lack suffici tissu braf test
also use later patient treatment spectrum standard-of-car treatment
begin lose effect help patient avoid invas biopsi identifi
new genom target identifi potenti clinic trials/off-label therapi
also use biopharmaceut compani identifi target
patient popul acceler translat scienc research acceler clinic
trial enrol acceler drug develop drive post-approv
clinic report design user-friendli deliv result
day quicker tumor panel take week fax portal
mobil devic report detail somat mutat detect patient blood
sampl provid associ treatment option avail clinic trial
near patient locat report depict guardant tumor respons map
visual represent show evolut somat mutat blood sampl
follow page show sampl patient report
diagnost tool
figur sampl clinic report patient diagnos non-smal cell lung cancer
initi coverag
diagnost tool
initi coverag
analyt valid perform evalu
order assess abil detect major class alter
relev treatment select point mutat indel insertions/delet copi
number amplif fusions/rearrang conduct
analyt valid studi orthogon valid method result
publish clinic cancer research
guardant observ test success rate studi compris
consecut sampl provid insight test perform
real-world clinic specimen overal detect rate ctdna
predominantli driven nsclc colorect breast
median variant allel frequenc measur rel frequenc
gene variant popul
result blind retrospect review compris consecut nsclc
sampl assess concord test tissu
genotyp sampl receiv clinic test laboratori show
diagnost tool
figur perform evalu peer-review public span multipl tumor type
initi coverag
key clinic trial public
prospect intervent multi-canc clinic util studi patient
across patient tissu genotyp option show object
respons rate ci diseas control rate ci
nsclc cohort patient test match pre-
specifi therapi patient treat match therapi
patient evalu importantli respons rate independ
variant allel frequenc vaf mutat found blood
guardant analyz clinic respons multi-cent case seri
test-detect target driver alter advanc nsclc vaf less
patient select target driver alter egfr
patient respond target therapi median progression-fre
surviv week patient under-genotyp larg due tissu
diagnost tool
figur show high posit predict valu across driver mutat compar liquid vs tissu test
initi coverag
guardantomni provid biopharma comprehens panel
guardantomni launch build guardant digit sequenc technolog
learn design pharmaceut custom use
comprehens genom profil tool help acceler clinic develop
program immuno-oncolog target therapi omni panel
breadth significantli larger compar
perform includ major gene evalu cancer drug
develop pipelin biomark immuno-oncolog applic includ
tumor mutat burden tmb guardantomni develop collabor
astrazeneca bristol-my squibb bm estim gh sell omni test
pharma price approxim may vari custom
recurr residu diseas test cancer survivor
program design pursu two opportun surveil
cancer patient complet cur cancer treatment potenti detect
recurr earliest stage detect residu diseas blood
cancer patient surgeri gh believ may identifi popul patient
residu diseas like benefit adjuv chemotherapi
treatment program seek provid definit test recurr
move beyond limit today method guardant recent made
lunar assay avail research use ruo thu enabl pharma compani
diagnost tool
initi coverag
academ research use identifi new drug develop opportun
program initi focu lung breast colon ovarian cancer
guardant launch ruo assay pharma custom late decemb
plan clia launch prospect clinic studi
lunar holi grail look bring early-stag cancer detect
screen asymptomat individu higher-risk develop cancer
guardant program seek develop accur afford blood
test widespread use among higher-risk asymptomat individu
guardant peg billion assum million
individu higher risk cancer us alon price
guardant market size american higher risk cancer includ
million peopl moder high hereditari risk develop breast
ovarian colon endometri prostat cancer base preval statist
report genet medicin censu data
million smoker age base cdc estim
million peopl high risk develop liver cancer due hepat
infect base estim hepatolog
guardant seek leverag data ten thousand advanc cancer liquid
biopsi sampl today plan leverag data thousand earli stage
cancer sampl develop test strong sensit specif earli
detect cancer guardant collabor investig cancer center
around world pursuit goal
exampl guardant work univers san francisco univers
colorado univers pennsylvania one collabor involv studi
patient higher risk develop lung cancer guardant plan show data
compar test rel standard care differenti earli
cancer vs benign nodul lung cancer
guardant also initi early-stag colon cancer among sever
cancer believ investor appreci potenti upsid
success among one cancer believ test would
well receiv clinic commun mark materi upsid guardant
stock price said path success launch like
take time materi invest
guardant goal launch simpl non-invas screen test routin
blood draw today exist method exist screen mani either invas
often keep complianc rate low costli lack test accuraci
lead larg number fals posit fals alarm reflex invas
costli often imperfect addit test procedur ad cost
healthcar system payor
exampl exist screen test lack sensit specif includ
prostate-specif antigen test prostat cancer test ovarian
cancer test pancreat test
perhap egregi screen modal found lung cancer
screen low-dos ct screen ldct recommend uspstf
grade adult age histori smoke
uspstf recommend annual screen lung cancer low-dos comput
tomographi ldct adult age year pack-year smoke
histori smoke quit within past year
diagnost tool
initi coverag
howev uspstf proce issu shortcom ldct includ
harm associ ldct screen includ false-neg false-posit
result incident find overdiagnosi radiat exposur false-posit
ldct result occur substanti proport screen person
posit result lead diagnosi cancer high-qual screen
program imag resolv false-posit result howev
addit high fals posit rate one survey report
estim million elig patient receiv ldct screen part result
known high fals posit rate cast doubt util perform ldct
part guardant program compani look combin somat
signatur addit import biomark area epigenom
signatur order enhanc sensit
reimburs guardant good start
avail offer remain limit
list price clinic patient current
medicar reimburs rate guardant done good
job contract certain health plan vari price estim
hover slightli medicar rate
guardant cover live flagship test vs
earli januari live end expect
number commerci cover live expand cours
particularli if/when guardant obtain fda approv
cover medicar sever cross shield plan
adopt reimburs polici cover non-smal
cell lung cancer nsclc reimburs polici heavili reliant
clinic data fda approv
coverag commerci payer focus nsclc repres
guardant clinic test volum guardant remain activ
dialogu expand coverag decis commerci payor guardant
contract bcb massachusett bcb fl horizon nj
carefirst bcb maryland bcb south carolina prioriti health medicar
nsclc name
diagnost tool
figur guardant steadili expand reimburs live plenti addit room
initi coverag
portion cover live januari note guardant sinc ad addit reimburs coverag cover live april
aforement payor determin analyt valid clinic
valid clinic util evid requir medic polici inclus nsclc
met addit certain lab benefit manag work health plan
informeddna kentmer cross al avalon cross nc
sc cover
medicar reimburs limit like expand meaning way
view may guardant award medicar local coverag determin
lcd palmetto gba propos limit coverag
patient advanc non-smal cell lung cancer palmetto gba moldx program
establish reimburs complet assess test data determin
clinic util coverag juli palmetto gba final lcd
nsclc patient meet certain clinic criteria set
reimburs rate guardant work close
palmetto obtain posit coverag decis submit detail dossier
analyt clinic data substanti test met medicar medic
necess requir addit noridian healthcar solut
medicar administr contractor respons medicar claim california
final lcd septemb
center medicar medicaid servic allow local
cover discret patient meet certain condit may
determin coverag test diagnost lab test patient cancer
test perform clia-certifi lab order treat physician
patient
either recurr relaps refractori metastat advanc stage iv
cancer
diagnost tool
initi coverag
 either previous test use test
primari diagnosi cancer repeat test use test
new primari cancer diagnosi made treat physician
 decid seek cancer treatment therapeut chemotherapi
nation coverag determin made evidence-bas process
center medicar medicaid opportun public
particip medicar releas landmark decis memo
advanc cancer patient provid among thing
coverag avail fda-approv companion vitro diagnost ivd next-
gener sequenc test offer within fda-approv label
decis memo cover molecular diagnost test similar
product companion diagnost cdx label fda approv
diseas state one rapid path obtain pan-canc medicar coverag obtain
fda approv cdx pan-canc tumor profil label
medicar payment lab test made clinic laboratori fee
schedul clf payment amount assign specif code april
congress pass protect access medicar act pama
includ chang way clinic lab servic paid medicar june
publish final rule implement report rate-set
requir pama pama lab receiv major medicar
revenu payment made clf requir report
begin everi year thereaft commerci payer payment rate
volum test perform use data calcul weight
median payment rate test use establish revis medicar clf
reimburs rate test
guardant recent began bill medicar test compani expect
subject report requir pama test furnish
januari medicar payment clinic dx lab test base upon report
commerci payer rate guardant subject next pama collect period
begin pay pama-calcul price understand
privat payor reimburs pay
medicar rate therefor dont expect pama erod price
fact may lead degre price increas
clinic data public
guardant nile studi build support blood-first test paradigm
late februari guardant announc interim analysi non-invasive
versu invas lung evalu nile studi featur patient test
abil detect seven guideline-recommend predict
genom biomark non-smal cell lung cancer egfr braf ret
nile studi identifi guideline-recommended-
biomark patient versu patient tradit tissu biopsi major data
point includ posit predict valu median turnaround time test
posit predict valu four genet target egfr
braf addit median time gh result day compar
day tissu biopsi view data set signific mileston
increas scale adopt full result present
american associ cancer research april
diagnost tool
figur nile studi identifi guideline-recommend biomark patient vs patient tradit tissu biopsi
initi coverag
leighl papadimitrakopoul american associ cancer research annual meet abstract
figur nile studi provid comprehens genom test guideline-recommend biomark
leighl papadimitrakopoul american associ cancer research annual meet abstract
diagnost tool
initi coverag
import upenn studi publish jama oncolog research upenn
abramson cancer center found could identifi mutat liquid
biopsi versu solid invas tissu biopsi alon publish find
jama oncolog studi oncologist use evalu patient
clinic action mutat guid initi subsequ treatment
decis among patient concurr plasma tissu next
gener sequenc unabl complet tissu test
found target mutat nearli twice mani patient
tissu biopsi alon patient vs tissu gh leverag data build
case transit tumor first blood first test paradigm believ
gh best-in-class comprehens liquid biopsi profil part led scienc
data
somat genom landscap patient advanced-stag cancer
clinic next-gener sequenc analysi circul tumor dna studi
look result liquid biopsi use test
span cancer type includ lung breast colon cancer prior studi
liquid biopsi studi limit modest-s cohort case studi
somat genom profil patient advanced-stag clinic cancer
determin frequenc somat ctdna alter per gene
compar previous describ tissu sequenc project
tcga studi conclud accuraci ctdna sequenc ppv assess
compar match tissu test patient cohort consist lung
breast colorect cancer ctdna clinic
sensit respect cancer-type-specif frequenc
mutual exclus pattern among major driver alter larg recapitul
seen tissu sequenc studi accuraci increas blood
tumor collect less six month apart
april clinic cancer research data retrospect analysi conduct
seri consecut lung cancer patient test
could compar tissu genotyp result perform
provid result show treatment-relev alter egfr
ret braf kra posit concord
tissu genotyp percent furthermor upon follow case
fusion neg tissu patient
respond treatment standard-of-car inhibitor studi also includ
blind blood-to-blood clinic valid studi cohort patient
demonstr nearli ident result compar well
valid liquid biopsi develop dana-farb cancer institut separ
analysi clinic sampl detect rate
circul tumor dna across tumor type
detect rate ctdna real-world patient sampl guardant conduct studi
compris consecut sampl provid insight test
perform real-world clinic specimen studi test success rate
observ overal detect rate ctdna consist high
predominantli driven nsclc colorect breast
prospect clinic outcom studi patient treat base multi-
cancer clinic util studi across patient tissu
genotyp option conduct august june
nsclc cohort patient test match pre-specifi therapi
patient treat match therapi patient
evalu object respons rate ci diseas
diagnost tool
initi coverag
control rate ci importantli respons rate
independ vaf mutat found blood
clinic relev action mutat detect ultra-low concentr
guardant analyz clinic respons case seri
target alter advanc nsclc twelv patient multicent seri
select target driver alter egfr vaf rang
eml-alk fusion vaf rang patient respond
target therapi median progression-fre surviv week
diagnost tool
figur invest significantli develop larg number public tabl
initi coverag
compani report tabl assembl canaccord genuiti
diagnost tool
figur invest significantli develop larg number public tabl
initi coverag
compani report tabl assembl canaccord genuiti
diagnost tool
figur invest significantli develop larg number public tabl
initi coverag
compani report tabl assembl canaccord genuiti
diagnost tool
initi coverag
may guardant launch guardant million initi seek
deploy compani test one million cancer patient within five year less
two year later order time
oncologist biopharma compani heavi invest
technolog clinic develop regulatory/reimburs sale forc
guardant look penetr consid market opportun
guardant also target meaning intern expans strateg
relationship joint ventur distributor guardant product current sold
countri
guardant prepar acceler commerci effort
 sell product clinician pharma compani
target sale organ includ direct rep clinic oncolog
specialist guardant process expand direct sale forc
rep expect done fda approv expect
late clinic sale rep target oncologist cancer center
basi guardant peer-review public publish clinic data
market lead posit liquid biopsi market pharma-focus rep target
pharma compani base valu provid drug develop
commerci guardant rep typic experi lab test
therapeut oncolog target custom includ academ research institut
network idn/payer-own system govern facil
offer product countri outsid us primarili
distributor relationship direct contract hospit gh identifi
larg opportun asia initi japan guardant hold ownership interest
joint ventur softbank form may acceler
commerci product asia middl east africa near-term
focu japan accord guardant death solid
tumor cancer japan larg portion compris lung gastric cancer
guardant ou commerci strategi driven involv clinic
program establish clinic util japan
softbank import joint-ventur partner investor gh softbank form
joint ventur amea inc commerci compani test
asia middl east africa guardant softbank evalu use
direct sale oper distribut model licens model market
term joint ventur agreement guardant paid ownership
interest jv affili softbank contribut ownership
lc-scrum-japan lc-scrum-japan nationwid genom screen project
across institut aim match metastat lung cancer patient
approv drug experiment therapi clinic trial lc-scrum-japan
screen patient target therapi sinc use tissu sampl
genom analysi decemb program announc goal screen
scrum-japan gi-screen liquid biopsi arm studi known gozila
gastrointestin cancer patient clinic trial therapi target specif
gene alter studi use advanc patient
whose cancer progress standard care anti-egfr treatment
diagnost tool
initi coverag
test posit amplif gene enrol clinic trial
explor effect combin target therapi studi
expect expand includ patient varieti gi cancer
guardant pharma-focus rep target major pharma compani promot
valu guardant test across full spectrum pharma activ earli
stage research clinic develop commerci decemb
guardant announc partnership astrazeneca develop
companion diagnost tagrisso guardantomni companion
diagnost imfinzi posit deal believ guardant success
astrazeneca like stimul addit interest addit larg pharma
screen treatment recurr
earli detect cancer screen highlight unmet need today
screen test earli cancer detect seek identifi diagnos patient
earliest stage diseas progress prior appear
symptom given absenc physic symptom tissu test consid
impract earli detect cancer current method earli cancer
detect includ singl protein biomark test imag biomark
omic test limit analyt clinic valid regularli face issu
high fals posit rate compani pursu blood-bas test earli cancer
screen often target singl cancer vs pan-canc multi-canc screen
protein test prostat cancer pancreat cancer ovarian
cancer suffer lack sensitivity/specif radiograph imag
suffer low specif high false-posit rate result nation lung
screen trial report new england journal medicin show low-
dose ct imag may identifi lung nodul heavi smoker
benign patient complianc anoth key challeng earli detect cancer-
guardant estim elig american non-compli
guideline-recommend colorect cancer screen line cologuard
manufactur exact scienc less estim
guardant goal program develop accur afford
screen test potenti high complianc use higher risk asymptomat
individu guardant defin high risk individu
moder high famili risk develop cancer
smoker age
individu hepat
guardant believ screen test use somat signatur may
insuffici detect earli stage cancer high sensit thu
program look add epigenom signatur enhanc perform
screen test
treatment select late-stag cancer patient
therapi select assay help clinician biopharma compani identifi advanc
stage cancer patient may benefit target therapi base uniqu
diagnost tool
initi coverag
characterist patient respons theyv standard-of-car
treatment therapi select assay use begin patient
treatment journey understand molecular profil tumor question
later journey monitor patient respons therapi
assay seek guid decis clinician enabl rang
applic biopharmaceut custom includ identifi target patient
popul acceler translat scienc research clinic trial enrol drug
develop post-approv commerci
biopharma compani increasingli interest sign companion diagnost
agreement diagnost compani often increas chanc drug
success clinic trial identifi select patient whose cancer
accord globaldata solid tumor oncolog clinic pipelin
target therapi immuno-oncolog therapi agent mani
target cancer specif molecular profil biomark fda approv
new drug doubl drug approv
averag approv per year
guardant seek provid solut address current limit therapi
select test given limit tissu biopsi guardant believ blood
test assess comprehens genom profil patient cancer
especi valuabl local commun set cancer patient
treat infrastructur expertis access tissu may limit
peg us therapi select market
test cours diseas anoth annual therapi select
opportun pharma assum tests/year price
pharma note price pharma rate
gh point pharma industri clinic pipelin immune-oncolog
seek add valu stage pharma drug develop includ prospect
estim base seer cancer registri statist
screen test cancer recurr seek identifi diseas recurr
earliest stage intervent treatment higher chanc success
american cancer societi estim solid tumor
cancer survivor us cancer recurr test conduct immedi
follow surgic remov tumor follow standard-of-car chemotherapi
patient remiss often time follow surgic remov
tumor patient given non-target chemo kill residu diseas
chemotherapi complet cancer survivor period check
oncologist evalu statu remiss current method detect
cancer recurr larg base monitor symptom physic
exam imag outsid tradit method number
compani commerci prognost predict molecular test seek
determin patient risk cancer recurr
guardant program strive provid definit diagnost test cancer
would use immedi follow surgic resect patient
tumor monitor tool subsequ year guardant believ test
diagnost tool
initi coverag
also enabl biopharmaceut compani identifi new opportun adjuv
drug develop therapi target earlier stage cancer
accord estim intern agenc research cancer iarc
million new cancer case million cancer death world-wide
global burden expect grow million new cancer
case million cancer death increas due number factor
includ growth age popul futur burden may even larger
due increas preval factor increas risk smoke unhealthi
diet physic inact factor develop countri world-wide total
number peopl aliv within year cancer diagnosi estim
million
guardant initi focus four type cancer lunar program lung
colon breast ovarian cancer highlight incid preval
four cancer data sourc american cancer societi
lung cancer new case per year us
three type lung cancer non-smal cell small cell lung carcinoid
tumor non-smal cell lung cancer nsclc common type account
lung cancer small cell account tend spread fairli
quickli fewer lung cancer lung carcinoid tumor grow slowli
rare spread lung cancer lead cancer killer men women
 moldx estim new case lung cancer
unit state repres roughli new cancer diagnos
cancer death addit estim surviv rate non-smal cell
lung cancer patient patient stage iv nsclc cdc
creat program nation comprehens cancer control program
offic offic smoke order reduc tobacco-
breast cancer new case per year us
women breast cancer death rate higher
cancer lung cancer approxim women us develop
invas breast cancer cours lifetim estim
new case invas breast cancer expect diagnos women
 along new case non-invas breast cancer
new case invas breast cancer expect diagnos men
man lifetim risk breast cancer breast cancer incid rate
 began decreas year averag annual rate
per one theori decreas partial
due reduc use hormon replac therapi hrt women
result larg studi call women health initi publish
result suggest connect hrt increas breast cancer risk
although death rate decreas sinc recent death
rate average annual rate per approxim women
 expect die breast cancer
diagnost tool
initi coverag
colon cancer new case per year us
exclud skin cancer colon cancer third common cancer diagnos
men women unit state american cancer societi estim
new case colon cancer new case rectal cancer
unit state per year incid rate averag
annual rate per death rate averag
annual rate per death rate declin sever decad
due implement screen colorect polyp cdc hope
reduc colon cancer incid death colorect cancer control
program provid fund state health depart univers
increas colon cancer screen rate among peopl age
ovarian cancer new case per year us
estim new case ovarian cancer
estim death incid rate case per
women death rate ovarian cancer rank
fifth cancer death among women account death
cancer femal reproduct system woman risk get ovarian cancer
lifetim lifetim chanc die ovarian cancer
demonstr need earli detect ovarian cancer
ovarian cancer found earli stage ovarian cancer
found earli patient live longer year diagnosi
two test frequent use transvagin ultrasound tvu blood
test howev mass found tvu cancer high level
caus common condit endometriosi disord
tissu line uteru present organ
analysi flatiron health health record databas publish august
spark debat valu comprehens genom sequenc precis
medicin studi found individu whose tumor analyz dozen
mutat nsclc dont seem surviv longer live better patient get
smaller limit gene-specif test note studi need
conduct demonstr
author note one challeng cgp mani patient arent receiv
drug need rather drug valuabl dr geoffrey oxnard
well-respect medic oncologist dana farber involv studi
weigh result sequenc advanc faster doctor abil
get target therapi patient oxnard state still valu commun
set base use dr oxnard opin patient get test
probabl better patient get test trial
get trial thu highlight valu liquid biopsi therapi select
test access clinic trial target therapi
diagnost tool
figur million american newli diagnos cancer year american die cancer year
initi coverag
diagnost tool
initi coverag
foundat medicin roch foundat medicin fmi acquir roch june
total compani valu billion trail fy revenu
y/i offer comprehens genom profil assay identifi
molecular alter patient cancer match relev target
therapi immunotherapi clinic trial foundat three test includ
foundationon cdx foundationon liquid foundationon heme
foundationon tissue-bas test foundationon liquid use whole blood
foundationon heme use tissu peripher whole blood bone marrow aspir
foundationon cdx first fda-approv broad companion diagnost
clinic analyt valid solid tumor foundationon cdx nation
coverag qualifi medicar medicar advantag patient across solid
tumor foundationon liquid provid target gene microsatellit instabl
result help direct therapi select clinic trial option
foundationon heme seek provid physician clinic action
inform help diagnost subclassif prognosi assess
target therapeut select hematolog malign sarcoma
cari life scienc privat cari precis medicin molecular profil
compani access clinic case cari suit
molecular profil offer assess dna rna protein reveal molecular
blueprint enabl physician cancer patient make precis
person treatment decis like precis medicin compani weve met
compani assert dna doesnt tell whole stori aggreg
multi-om solut research cari believ thousand molecular
featur combin clinic outcom data feed proprietari
machin learn system dean analyt compani goal feed data
beast identifi predictor immun oncolog among applic
tempu privat form tempu privat held compani base
chicago seek advanc precis medicin collect analysi
molecular clinic data august tempu complet seri
round led bailli gifford row price revolut growth new enterpris
associ nea other tempu rais million to-dat valu
billion compani use machin learn next-gen sequenc ai
assist imag recognit seek acceler insight new discoveri
enabl physician make time data-driven clinic decis clia/cap
analyz gene xe analyz whole exom gene
xt target panel gene tempu provid broad rang dna rna
sequenc proteom stain servic provid germlin somat
molecular data physician
launch privat held compani base baltimor develop
portfolio tissue-bas liquid biopsi genom product lab pgdx seek
uncov key genom driver clinic respons select immun
checkpoint inhibitor base microsatellit instabl tumor mutat burden
compani aim make test avail patient treat provid
regul ivd test run local laboratori juli compani
announc pgdx elio plasma resolv test obtain breakthrough devic
design fda elio test qualit blood-bas in-vitro diagnost
test use target high throughput parallel-sequenc detect snv indel
amplif rearrang microsatellit instabl broad multi-
diagnost tool
initi coverag
gene panel circul cell-fre dna pgdx hope launch first kit liquid
biopsi test could run local lab across world rather requir
sampl ship one particular locat could enabl faster test
turnaround time bristol-my squibb new enterpris associ nea co-l
seri round januari pgdx found highli
respect physician dr lui diaz dr velculescu spun john
 leader next-gener sequenc provid lab
biopharma compani research center sequenc instrument
product applic research use offer
product use clinic oncolog market april sign global
strateg partnership loxo oncolog acquir develop
commerci multi-gen panel broad tumor profil result
distribut ngs-base companion diagnost cdx pan-canc indic
offer trusight panel includ trusight oncolog panel
ngs-base tumor profil assay analyz gene interest rna
gene support identif relev dna rna variant implic
biomark tumor mutat burden tmb microsatellit instabl
guardant co-found helmi eltoukhi amirali telasaz previous work
senior director advanc technolog senior director diagnost
research helmi coinventor ilmn iseq system acquir
 leader blood-bas non-invas prenat test nipt
engag discoveri develop commerci genet
test servic name preconcept prenat genet test servic
product includ panorama market-lead nipt test horizon lead carrier
screen test recent evercord privat cord blood tissu bank
servic offer signatera oncolog test research-us number
lead pharmaceut compani applic recurr monitor
residu diseas detect look launch signatera liquid biopsi test
cancer patient launch first mover
recurr monitor potenti ahead guardant launch cancer
patient time yet known
grail privat grail found goal develop
blood-bas pan-canc screen test earli stage cancer guardant health
initi develop solut advanc cancer treatment monitor
eventu goal develop recurr monitor earli stage screen grail
initi target pan-canc multi-canc screen test early-stag cancer
sinc incept grail rais total investor includ
ventur partner amazon bezo expedit gate ceo jennif cook
previous roche/genentech global head clinic oper replac found
ceo jeff huber decemb
 focus develop commerci non-
invas molecular screen test earli detect prevent colorect
cancer exass cologuard stool-bas dna test identifi cancer detect
genet mutat colorect cancer cell test includ protein biomark
dna point mutat biomark differ dna methyl biomark one
addit dna biomark confirm appropri amount stool dna
diagnost tool
initi coverag
analyz individu sampl current develop blood-bas
biomark earli detect esophag breast lung liver pancreat cancer
cheaper sensit invas biopsi capabl
test one indic colon cancer billion market cap
freenom privat freenom early-stag pre-commerci privat compani
base san francisco bay area freenom develop artifici intellig
ai platform seek detect cancer earliest stage help clinician
optim next gener precis therapi freenom develop liquid
biopsi test use multi-om approach early-stag cancer screen
hope enter larg colon cancer screen market sometim around
base understand freenom hope combin cell-fre dna
addit analyt like protein immun signal possibl dna
methyl analyt order develop accur test capabl screen
cancer freenom indic plan develop screen test cancer
includ colon breast high-risk lung high-risk ovarian among other
diagnost tool
figur manag team believ team highli capabl still underappreci lack familiar
initi coverag
diagnost tool
figur board director believ guardant leverag outstand board
initi coverag
diagnost tool
initi coverag
premium valuat gh trade premium multipl rel mani
diagnost compani given gh best-in-class liquid biopsi portfolio huge
believ valuat warrant bad news regulatori reimburs
time product launch oper shortfal could result materi move
lower stock
risk obtain fda approv flagship test pan-
cancer label current ldt laboratory-develop test gh
voluntarili take assay fda expedit access pathway via
breakthrough devic design eap design expect give
prioriti review access senior fda offici doesnt guarante fda approv
guardant view fda approv signific mileston need facilit
commerci adopt extend approv timelin failur obtain fda
risk obtain pan-canc medicar coverag today gh medicar
coverag nsclc guardant expect obtain final pan-
cancer medicar coverag decis base expect fda approv
guardant expect nation coverag determin ncd
test delay obtain pan-canc coverag could limit compani futur
volum revenu growth
manag execut risk given technic natur develop liquid biopsi
gh commerci success depend manag abil launch new panel
secur addit reimburs regulatori new label win guardant health
provid guidanc shortfal rel guid mark materi risk
risk launch commerci compani largest market
opportun gh peg market opportun high
risk individu huge opportun requir high sensit specif
across larg clinic trial cohort gh releas promis pilot data
rel small sampl size guardant experi setback poor
result delay/cancel launch gh growth potenti would
competit guardant compet directli compani provid
comprehens genom profil therapi select foundat medicin
roch cari life scienc tempu other think guardant like
compet recurr monitoring/residu diseas market among
other guardant may compet screen diagnost
compani includ colorect cancer screen possibl grail
launch
relianc sole supplier guardant reli heavili sole sequenc
provid gh activ suppli agreement decemb automat
renew thereaft contract either parti option opt
agreement notic year advanc opt gh may struggl
find replac sequenc meet perform demand
reimburs risk cover live nsclc
think fda approv like drive broader payor adopt larg health insur
aet other current coverag decis guardant
fail increas reimburs coverag particularli across cancer state
nsclc would meaning limit opportun
diagnost tool
initi coverag
risk relat oper larg grow lab san francisco bay area home
earthquak san francisco bay area prone earthquak larg
earthquak could interrupt lab oper compani lab headquart
risk relat intern expans guardant offer test countri
outsid establish amea softbank facilit
expans asia middl east africa engag clinic trial work
japan lack compel data regulatori setback could delay expans plan
ou addit guardant could struggl facilit adopt emerg market
due pricing/reimburs test
valuat comp
stock appreci sinc ipo octob
recogn easi reconcil stock move particularli rel peer
group revenu estim anytim soon gh trade consensu
revenu guardant target huge global market larger
compani diagnost estim believ way valu
compani look least sever year guardant succeed
launch one screen test market part initi
see materi upsid rel estim
initi buy rate price target use multipl
revenu estim discount back year discount
show expect guardant grow top line
respect faster peer expect
grow base consensu estim
believ premium multipl appropri given guardant technolog
leadership posit us therapi select market opportun
penetr us recurr monitor market us opportun
penetr screen market us opportun global scale
initi japan market share leadership blood-bas liquid biopsi
market size guardant global billion
seen figur peer trade averag
consensu revenue estim respect though key peer
trade averag assign
ev/revenu multipl gh revenu estim deriv pt
believ multipl estim appropri given leadership posit
blood-bas liquid biopsi huge estim rel peer de-
risk commerci launch given success launch flagship
test given proprietari technolog think guardant well posit enter
penetr oncolog liquid biopsi market peg unit state
approxim billion
comp group made well posit precis medicin diagnost
compani target cancer diagnost pharma/research market
comp group includ specialti laboratori instrument compani
enabl dna rna protein multi-om precis medicin view
fmi acquir roch gh closest comp given
market-lead posit manag team minim penetr tam
remind foundat medicin acquir roch note gh
diagnost tool
initi coverag
estim larger exass estim cologuard
ilmn estim though size
view gh global us japan eu assum
billion assum cologuard liquid biopsi pipelin
figur guardant trade revenu estim signific premium versu consensu peer group averag
canaccord genuiti estim factset foundat medicin acquir roch billion revenu estim fmi assum midpoint compani guid
prior acquisit roch grown y/i foundat medicin revenu assum y/i growth rate base canaccord genuiti estim
diagnost tool
figur gh trade consensu revenue estim vs peer trade given view guardant grow faster
peer much larger total address market believ investor need valu guardant out-year rev use
initi coverag
diagnost tool
initi coverag
recent palmetto lcd expand coverag beyond nsclc solid
post draft local coverag determin lcd expand medicar coverag
assay advanc non-smal cell lung cancer nsclc
dozen advanc solid tumor cancer type guideline-recommend genom
target first liquid biopsi genom profil assay receiv broad local
draft coverag across multipl solid tumor member public comment
propos coverag test may june
base pan-canc draft coverag determin issu palmetto
cover patient non-cn origin solid tumor meet
criteria ncd next-gen sequenc follow condit met
tissue-bas genom profil possibl either quantiti tissu
suffici invas biopsi medic contraind specif nsclc
tissue-bas profil shown action mutat
patient candid treatment drug either fda-
clear patient cancer nccn nccn recommend
patient cancer
fda-approv indic nccn recommend requir inform
presenc absenc biomark test
initi palmetto coverag decis limit nsclc certain condit
highlight exist level medicar reimburs coverag
base initi palmetto decis
cover follow condit met
patient diagnos advanc stage iiib iv non-smal cell lung
cancer nsclc
patient treat result egfr singl nucleotid variant snv
indel rearrang express avail
addit tissue-bas profil possibl either quantifi tissu
suffici invas biopsi medic contraind
patient progress chemo io treatment never
test egfr mutat
snv indel rearrang tissue-bas profil
possibl quantiti tissu suffici
patient show progress egfr tyrosin kinas inhibitor tki
polici provid limit coverag plasma-bas
comprehens somat genom profil test hereaft call cgp patient
diagnosi result egfr singl nucleotid variant snv insert
delet indel rearrang express
diagnost tool
initi coverag
avail tissue-bas profil possibl either quantiti tissu
suffici invas biopsi medic contraind
progression- patient progress chemo io treatment
never test egfr snv indel rearrang
tissue-bas profil possibl quantiti tissu suffici
patient progress egfr tyrosin kinas inhibitor tki
decis memo next-gener sequenc medicar beneficiari
center medicar medicaid servic rule next-gener
sequenc diagnost lab test reason necessari cover
medicar us perform clia-certifi lab order
treat clinician follow condit met
patient
either recurr relaps refractori metastat advanc stage
cancer
either test use test
primari diagnosi cancer repeat test use
test new primari cancer diagnosi made
treat clinician
decid seek treatment cancer chemo
diagnost lab test use need
fda clearanc approv companion vitro diagnost
fda clear indic use patient cancer
result provid treat clinician manag patient use
report identifi treatment patient
medicar administr contractor determin coverag
sequenc base test diagnost lab test patient cancer
test perform clia-certifi lab order treat clinician patient
either recurr relaps refractori metastat advanc stage
cancer
either test use test primari
diagnosi cancer repeat test use sequencing-bas test
new primari cancer diagnosi made clinician
decid seek addit treatment chemo
diagnost tool
initi coverag
american associ cancer research
 combin genom epigenom assess cell-fre circul tumor
dna ctdna improv assay sensit early-stag colorect cancer
studi goal studi aim evalu use guardant lunar assay
early-stag screen tool colorect cancer guardant plasma-onli
analysi bioinformat classifi filter non-tumor deriv variant
method use larg databas cell-fre dna cfdna profil gener
advanc cancer patient author design target sequenc assay
detect somat variant methyl alter epigenom variat
transcript factor bind site associ total cfdna extract
partit base methyl level analyz data filter use
variant classifi differenti tumor- non-tumor-deriv alter without
priori knowledg tissu germlin sequenc result machin learn model
train cfdna sampl late stage earli stage pt
age-match cancer-fre control independ test set plasma
sampl collect pt stage i-iv prior week
 total sampl surgic resect age-match cancer-fre
control similarli analyz test set
result pt male median age diagnosi
year rang stage distribut stage i/ii stage
stage iv pt post-surg sampl clinic follow-up
avail median post-surgeri follow-up day rang util
assay pre-surgeri ctdna detect rate stage i/ii
stage stage iv epigenom analysi significantli enhanc ctdna
detect rel somat mutat analysi alon vs
specif age-match cancer-fre control
variant detect epigenom analysi bioinformat classifi filter non-
tumor deriv variant ctdna detect rate earli stage i-iii
confid interv specif far outperform
detect rate somat sequenc variant detect alon clinic follow-up
on-going evalu post-surgeri ctdna detect rate diseas recurr
result signific implic clinic util ctdna earli stage
guardant present updat version data guardant
updat data present result patient abstract
publish ahead age-match cancer-fre control
prior abstract guardant data demonstr sensit set
specif use higher specif cutoff sensit came
respect perform lunar assay cancer stage
includ specif guardant lunar assay deliv sensit
stage ii iv cancer
diagnost tool
initi coverag
 novel genom differ cell-fre circul tumor dna cfdna
profil earli versu older onset colorect cancer
studi goal studi aim compar cfdna genom profil advanc
stage iib-iv colorect cancer patient age effort
improv understand treatment patient younger cohort
method consecut advanc pt receiv clinic cfdna test
analyz cfdna analysi includ next
gen sequenc gene assess singl nucleotid variant snv
insertion/delet alter indel fusion amplif amp high
microsatellit instabl msi-h statu avail subset case
characterist mutat frequenc compar
group exclud variant uncertain signific synonym alter
gene specif mutat frequenc compar fisher exact test
result stage iiib-iv pt test alter detect
cfdna
cohort male cohort male cohort
median five alter per pt rang rang median
maximum variant allel fraction includ co-occur amp
cohort rang cohort rang
test pt msi-h detect case
case signific cohort snv indel frequent
apc kra howev mutat apc kra
frequent
atm mutat common amp cohort egfr
braf may reflect aneuploidi myc braf myc
amp frequent observ cohort ret
fusion seen cohort
conclus first comparison cfdna find
advanc signific differ mutat amp frequenc sever
gene observ includ gene import prognosi therapi select
kra target biomark msi-h fusion
present age group previous unreport find may due
strength cfdna analysi includ larger sampl size uniform
cancer stage stratif mutat type result may help improv
understand treatment
 use comprehens cell-fre circuat tumor dna cfdna analysi
identifi genom biomark newli diagnos advanc non-smal cell lung cancer
studi goal assess perform cfdna compar standard care soc
tissue-bas genom test identifi guidelin recommend alter nsclc
pt assess whether cfdna test non-inferior tissue-bas test
method prospect multicent studi blood sampl treatment-nav
stage iiib-iv nsclc pt test use next-gener
sequenc cfdna panel compar soc tissu test primari
object demonstr non-inferior cfdna vs tissu analysi
detect guideline-recommend biomark includ kra nsclc ni
margin rate incomplet tissu genotyp defin
proport pt biomark neg tissu incomplet genotyp
guideline-referenc biomark exploratori analys includ estim
posit predict valu ppv cfdna tissu genotyp biomark
discoveri rate tissu test alon vs tissu plu cfdna test
diagnost tool
initi coverag
result metastat nsclc pt enrol august
includ interim analysi primari object non-inferior
met action mutat identifi cfdna vs tissu
tissu test incomplet pt
major biomark neg pt tissu genotyp fewer
recommend biomark commonli egfr ppv cfdna
egfr alter addit
cfdna increas biomark detect rate
includ neg assess quantiti suffici
qn biomark tissu
conclus prospect multi-cent studi demonstr comprehens
highli sensit cfdna assay non-inferior soc tissu test
detect guideline-recommend action genom alter nsclc
addit cfdna test algorithm time diagnosi markedli improv
biomark detect rate tissu negative/non-assess pt ppv cfdna
assay util high support use cfdna treatment select
result demonstr clinic util comprehens cfdna genotyp identifi
guideline-recommend biomark newli diagnos advanc nsclc pt
 colom colorect cancer liquid biopsi screen protocol
studi goal primari object studi perform blood-bas genom
profil patient treatment refractori metastat colorect cancer
facilit accrual molecularli assign therapi obtain patient-match
tumor tissu cell free dna peripher blood facilit clinic annot
genom analys secondari correl object explor mechan
acquir resist molecularli assign therapi explor correl
cfdna mutat burden allel frequenc copi number clinic
outcom object respons rate progression-fre surviv overal
method colom colorect cancer liquid biopsi screen protocol
molecularli assign therapi phase ii umbrella screen
protocol sponsor academ commun cancer research unit accru
consortium studi util identifi action genom alter
mcrc patient assess impact molecularli assign therapi
accordingli individu companion studi elig mcrc patient must
progress intoler contraind treatment
monoclon antibodi mab anti-epiderm growth factor receptor egfr mab
ra wild-typ companion studi dynam current includ
patient whose tumor either ras/braf wild-typ amplifi fgfr alter
ra mutat without known action alter addit companion
studi activ develop
studi design colom prospect studi estim enrol
particip accord nih clinicaltri gov websit studi kick
begin estim primari complet date novemb
studi expect complet secondari outcom measur novemb
diagnost tool
initi coverag
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
canaccord genuitymark massaro statement revenu revenu precis oncolog develop profit oper debt incom loss incom incom incom incom loss attribut net earn loss per share chg incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmepsnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmmargin ratenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmtot lab test total gh revenu model
initi coverag
diagnost tool
canaccord genuitymark massaro volum revenu chg chg product revenu stage cancer recurr cancer detect servic rev chang test access chg chg product clinic test access chg pharma test access chang stage cancer rev chg test access chg chg test test access chg chg test penetr rate therapi recurr detect rev chg test access chg chg q/qnmnmnmnmnmnmnmnmclinic test test access chg chg test cancer detect rev chg y/ynmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmclin test access chg y/ynmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnm chg q/qnmnmnmnmnmnmnmnmnmnmnmclinic test asp test access chg chg q/qnmnmnmnmnmnmnmnmnmnmnmpharma test asp stage cancer recurr cancer detect stage cancer recurr cancer detect gh
initi coverag
